Forest Laboratories Presents Analysis Of Two Positive Pivotal Phase III Studies Of Ceftaroline For The Treatment Of Community-Acquired Pneumonia (CAP)

Forest Laboratories, Inc (NYSE: FRX) presented at the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco new data from a complete analysis of FOCUS 1 and FOCUS 2, two global multicenter Phase III studies of ceftaroline for the treatment of community-acquired pneumonia (CAP) in hospitalized patients.